Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bladder cancer
Biotech
enGene drops cystic fibrosis program to focus on bladder cancer
enGene is halting work on a cystic fibrosis program to focus resources on moving its lead candidate further into bladder cancer.
James Waldron
Jun 14, 2024 8:20am
CG sets new bar in bladder cancer, months after huge IPO
May 3, 2024 11:23am
CG Oncology plans IPO ahead of phase 3 bladder cancer readout
Jan 3, 2024 8:25am
ImmunityBio inks $210M royalty deal to get cancer drug to market
Jan 2, 2024 7:41am
Second layoff wave hits ImmunityBio in less than a year
Sep 22, 2023 11:22am
CG raises $105M crossover round to fund phase 3 cancer trial
Aug 2, 2023 9:07am